Pharma Update

Advancing new modalities across key oncology pathways Bispecifics / trispecifics Neoantigen vaccines Degraders Cyclic peptides Cell Therapies PROTABS (Proteolysis-targeting antibody) TCR T cell Tumor Target Oncogenic pathways/drivers Synthetic lethality/DNA damage response T-cell redirection Synthetic immunity Tumor microenvironment Immunomodulation Adaptive immunity T-cell generation Lineage dependencies Explore biology of early disease and transform treatment of cancer Roche 81

View entire presentation